Press Release: Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Company to present an update of its ongoing
Dow JonesApr 24 10:05 ET
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
First Data Demonstrating Application of PREDATOR Platform in Immune-Mediated Diseases WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (
GlobeNewswireApr 23 08:00 ET
Buy Rating Affirmed for Werewolf Therapeutics on Promising PREDATOR Platform Prospects and Strong Pipeline Potential
TipRanksApr 19 10:06 ET
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
Yahoo FinanceApr 15 12:00 ET
Institutional Owners May Ignore Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Recent US$53m Market Cap Decline as Longer-term Profits Stay in the Green
Key Insights Institutions' substantial holdings in Werewolf Therapeutics implies that they have significant influence over the company's share price 50% of the business is held by the top 6 sharehol
Simply Wall StApr 13 10:39 ET
Analysts Are Bullish on Top Healthcare Stocks: Lucid Diagnostics (LUCD), Werewolf Therapeutics (HOWL)
TipRanksApr 10 13:50 ET
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
Werewolf Therapeutics (Nasdaq: HOWL) is presenting preclinical data on development candidates WTX-518 and WTX-712 in posters at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.
GlobeNewswireApr 5 16:30 ET
Express News | JMP Securities Initiates Coverage On Werewolf Therapeutics With Market Outperform Rating, Announces Price Target of $12
Moomoo 24/7Apr 3 04:47 ET
Werewolf Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/03/2024 88.09% JMP Securities → $12 Initiates Coverage On → Market Outperform 03/07/2024 135.11% HC Wai
BenzingaApr 3 04:42 ET
Buy Rating for Werewolf Therapeutics: Innovation and Financial Stability Signal Promising Future in Immunotherapy
TipRanksApr 3 01:06 ET
Buy Rating Affirmed for Werewolf Therapeutics With Anticipated Surge on WTX-124 Phase 1 Data Release
TipRanksMar 11 00:47 ET
Werewolf Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Yahoo FinanceMar 9 08:50 ET
Werewolf Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Werewolf Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 7 12:09 ET
HC Wainwright & Co. Maintains Buy on Werewolf Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Andres Maldonado maintains Werewolf Therapeutics with a Buy and maintains $15 price target.
Analyst UpgradesMar 7 11:58 ET
Buy Rating Reiterated for Werewolf Therapeutics Amid Promising INDUKINE Platform Developments
TipRanksMar 7 11:45 ET
Recap: Werewolf Therapeutics Q4 Earnings
Werewolf Therapeutics (NASDAQ:HOWL) reported its Q4 earnings results on Thursday, March 7, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsWerewolf Therapeutics beat
BenzingaMar 7 09:00 ET
Werewolf Therapeutics Announces CSO Retirement Date
TipRanksMar 7 07:23 ET
Werewolf Therapeutics Q4 EPS $(0.33) Beats $(0.43) Estimate, Sales $1.50M Miss $1.94M Estimate
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.43) by 23.26 percent. This is a 15.38 percent increase over losses o
BenzingaMar 7 07:11 ET
Werewolf Therapeutics: As of Dec 31, Cash and Cash Equivalents Were $134.3M >HOWL
Werewolf Therapeutics: As of Dec 31, Cash and Cash Equivalents Were $134.3M >HOWL
Dow JonesMar 7 07:03 ET
Werewolf Therapeutics: Preliminary Data From Phase 1 Clinical Trial of WTX-330 Expected in the 2Q of 2024 >HOWL
Werewolf Therapeutics: Preliminary Data From Phase 1 Clinical Trial of WTX-330 Expected in the 2Q of 2024 >HOWL
Dow JonesMar 7 07:02 ET
No Data
No Data